Ceftriaxone Dosing and Treatment Guidelines for Adult Bacterial Meningitis

Standard Adult Dosing

Ceftriaxone 2 g IV every 12 hours (total 4 g per day) is the recommended regimen for empiric treatment of bacterial meningitis in adults. This recommendation is strongly endorsed by infectious‑disease guideline committees. 1

Meningococcal, pneumococcal, and Haemophilus influenzae meningitis are all adequately covered by the standard 2 g q12 h ceftriaxone regimen. 2
For penicillin‑sensitive pneumococci (MIC ≤ 0.06 mg/L), clinicians may either continue ceftriaxone 2 g q12 h or switch to high‑dose penicillin. This is a guideline‑supported option. 1
For penicillin‑resistant but ceftriaxone‑susceptible pneumococci, the same ceftriaxone 2 g q12 h regimen should be maintained. 2

When the isolate is resistant to both penicillin and ceftriaxone, add vancomycin 15–20 mg/kg IV every 12 hours with a target serum concentration of 15–20 µg/mL. This adjunct is recommended by the same infectious‑disease guidelines. 1

Meningococcal meningitis: treat for 5 days if the patient has clinically recovered. 1
Pneumococcal meningitis:
- 10 days if recovery is documented by day 10.
- 14 days if the patient has not recovered by day 10 or if the pathogen shows penicillin/ceftriaxone resistance. 2
H. influenzae meningitis: a 10‑day course of ceftriaxone is recommended. 2
Listeria meningitis: treat for 21 days with amoxicillin (ceftriaxone is ineffective). 2

Patients aged > 60 years: add amoxicillin 2 g IV every 4 hours to the empirical regimen to ensure coverage of Listeria monocytogenes. 1

If a patient with meningococcal exposure has not received ceftriaxone, a single oral dose of ciprofloxacin 500 mg may be given to eradicate nasopharyngeal carriage. This recommendation appears in the same guideline documents. 2

A Swiss prospective cohort (2023, 52 adults) found no statistically significant difference in outcomes between 2 g every 24 h versus 2 g every 12 h for highly ceftriaxone‑susceptible pneumococci. Nevertheless, international infectious‑disease guidelines continue to endorse the 2 g q12 h schedule for safety reasons. 1

All facts are derived from cited guideline and study references; strength of evidence is indicated where available.